(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...
Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are ...
Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, ...
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software.
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...
Marks the Completion of NanoACTIV Integration Across the Company’s Entire Additively Manufactured and Wrought Titanium Spinal ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results